Sight Sciences (SGHT) stock: insider trades, news & valuation
Net sellingShare price and insider trades
Sight Sciences insider trading at a glance (Oct 9, 2026): in the past 12 months, 1 insider bought $185K and 6 sold $2.9M of SGHT stock on the open market.
Get emailed when insiders cluster-buy stocks like SGHT
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
SGHT insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $653K | 5 |
| Q3 2026 | — | 0 | $448K | 6 |
| Q2 2026 | $69K | 1 | $377K | 7 |
| Q1 2026 | — | 0 | $877K | 16 |
| Q4 2025 | $116K | 1 | $711K | 9 |
Valuation, profit and volume
Summary
Over the past 12 months, 1 Sight Sciences, Inc. insider reported open-market purchases totaling $185K, while 6 insiders reported sales totaling $2.9M. Among insiders with enough purchase history to measure, Staffan Encrantz (Director) has the highest Insider Score at 59. 26 of 43 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Oct 5SEC | Paul BadawiCEO, President | Sell Plan | 29,6536,092,819 held (−0%) | $9.05 | $268K | -1.8% | — |
| Oct 5SEC | Alison BauerleinCOO | Sell Plan | 25,260639,449 held (−4%) | $8.85 | $224K | +0.4% | — |
| Oct 5SEC | David BadawiCTO | Sell Plan | 7,7971,975,075 held (−0%) | $9.05 | $71K | -1.8% | — |
| Oct 5SEC | James RodbergCFO | Sell Plan | 7,208216,829 held (−3%) | $8.85 | $64K | +0.4% | — |
| Oct 5SEC | Brenton TaylorEvp, Operations & R&D | Sell Plan | 2,988261,990 held (−1%) | $8.85 | $26K | +0.4% | — |
| Jul 6SEC | Paul BadawiCEO, President | Sell Plan | 28,6846,122,472 held (−0%) | $5.42 | $155K | +64.0% | — |
| Jul 6SEC | Alison BauerleinCOO | Sell Plan | 24,184664,709 held (−4%) | $5.36 | $130K | +65.9% | — |
| Jul 6SEC | Jeremy B. HaydenGeneral Counsel | Sell Plan | 12,733357,037 held (−3%) | $5.51 | $70K | +61.3% | — |
| Jul 6SEC | David BadawiCTO | Sell Plan | 7,4181,982,872 held (−0%) | $5.51 | $41K | +61.3% | — |
| Jul 6SEC | James RodbergCFO | Sell Plan | 6,902224,037 held (−3%) | $5.36 | $37K | +65.9% | — |
| Jul 6SEC | Brenton TaylorEvp, Operations & R&D | Sell Plan | 2,829264,978 held (−1%) | $5.42 | $15K | +64.0% | — |
| Jun 11SEC | Staffan EncrantzDirector | Buy | 14,1001,434,283 held (+1%) | $4.88 | $69K | +82.2% | 59 |
| May 19SEC | Alison BauerleinCOO | Sell Plan | 12,728688,893 held (−2%) | $5.12 | $65K | +73.6% | — |
| Apr 9SEC | Jeremy B. HaydenGeneral Counsel | Sell Plan | 13,761369,770 held (−4%) | $3.55 | $49K | +150.4% | — |
| Apr 9SEC | James RodbergCFO | Sell Plan | 7,231230,939 held (−3%) | $3.55 | $26K | +150.4% | — |
| Apr 3SEC | Paul BadawiCEO, President | Sell Plan | 29,2446,151,156 held (−0%) | $3.70 | $108K | +140.3% | — |
| Apr 3SEC | Alison BauerleinCOO | Sell Plan | 25,874701,621 held (−4%) | $3.48 | $90K | +155.5% | — |
| Apr 3SEC | David BadawiCTO | Sell Plan | 8,1681,990,290 held (−0%) | $3.48 | $28K | +155.5% | — |
| Apr 3SEC | Brenton TaylorEvp, Operations & R&D | Sell Plan | 2,869267,807 held (−1%) | $3.70 | $11K | +140.3% | — |
| Jan 21SEC | Paul BadawiCEO, President | Sell Plan | 22,3626,025,840 held (−0%) | $6.62 | $148K | +34.3% | — |
| Jan 21SEC | Jeremy B. HaydenGeneral Counsel | Sell Plan | 6,308267,611 held (−2%) | $6.62 | $42K | +34.3% | — |
| Jan 21SEC | David BadawiCTO | Sell Plan | 4,8361,912,273 held (−0%) | $6.62 | $32K | +34.3% | — |
| Jan 21SEC | James RodbergCFO | Sell Plan | 2,616151,230 held (−2%) | $6.62 | $17K | +34.3% | — |
| Jan 6SEC | Paul BadawiCEO, President | Sell | 25,3565,937,146 held (−0%) | $7.43 | $188K | +19.7% | — |
| Jan 6SEC | Paul BadawiCEO, President | Sell | 11,8705,925,276 held (−0%) | $7.48 | $89K | +18.9% | — |
| Jan 6SEC | Alison BauerleinCOO | Sell | 10,896609,630 held (−2%) | $7.82 | $85K | +13.7% | — |
| Jan 6SEC | Jeremy B. HaydenGeneral Counsel | Sell Plan | 9,385247,205 held (−4%) | $7.82 | $73K | +13.7% | — |
| Jan 6SEC | Alison BauerleinCOO | Sell | 9,647599,983 held (−2%) | $7.48 | $72K | +18.9% | — |
| Jan 6SEC | James RodbergCFO | Sell | 4,405154,440 held (−3%) | $7.82 | $34K | +13.7% | — |
| Jan 6SEC | David BadawiCTO | Sell | 3,6951,917,109 held (−0%) | $7.48 | $28K | +18.9% | — |
| Jan 6SEC | David BadawiCTO | Sell | 3,0511,920,804 held (−0%) | $7.82 | $24K | +13.7% | — |
| Jan 6SEC | David BadawiCTO | Sell | 2,9141,923,855 held (−0%) | $7.43 | $22K | +19.7% | — |
| Jan 6SEC | Jeremy B. HaydenGeneral Counsel | Sell Plan | 1,785245,420 held (−1%) | $7.48 | $13K | +18.9% | — |
| Jan 6SEC | Brenton TaylorEvp, Operations & R&D | Sell | 619170,212 held (−0%) | $7.48 | $5K | +18.9% | — |
| Jan 6SEC | James RodbergCFO | Sell | 594153,846 held (−0%) | $7.48 | $4K | +18.9% | — |
| Dec 18SEC | Staffan EncrantzDirector | Buy | 13,9581,391,922 held (+1%) | $8.31 | $116K | +7.0% | 59 |
| Dec 3SEC | James RodbergCFO | Sell | 2,518158,845 held (−2%) | $8.25 | $21K | +7.8% | — |
| Nov 26SEC | Jeremy B. HaydenGeneral Counsel | Sell Plan | 44,850256,590 held (−15%) | $8.08 | $362K | +10.0% | — |
| Nov 18SEC | Brenton TaylorEvp, Operations & R&D | Sell | 14,418170,831 held (−8%) | $7.06 | $102K | +25.9% | — |
| Nov 14SEC | Jeremy B. HaydenGeneral Counsel | Sell Plan | 3,150256,590 held (−1%) | $8.01 | $25K | +11.0% | — |
| Oct 8SEC | Brenton TaylorEvp, Operations & R&D | Sell | 591185,249 held (−0%) | $3.37 | $2K | +163.8% | — |
| Oct 3SEC | Paul BadawiCEO, President | Sell | 24,4415,962,502 held (−0%) | $3.34 | $82K | +166.2% | — |
| Oct 3SEC | Alison BauerleinCFO | Sell | 19,948597,520 held (−3%) | $3.30 | $66K | +169.4% | — |
| Oct 3SEC | Jeremy B. HaydenGeneral Counsel | Sell | 9,731256,590 held (−4%) | $3.27 | $32K | +171.9% | — |
| Oct 3SEC | David BadawiCTO | Sell | 6,0331,864,992 held (−0%) | $3.27 | $20K | +171.9% | — |
Insiders at Sight Sciences, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Paul BadawiCEO, President | — | $1.0M | Oct 5, 2026 | — |
| Alison BauerleinCOO | — | $732K | Oct 5, 2026 | — |
| Jeremy B. HaydenGeneral Counsel | — | $667K | Jul 6, 2026 | — |
| Staffan EncrantzDirector | $185K | — | Jun 11, 2026 | 59 |
| David BadawiCTO | — | $265K | Oct 5, 2026 | — |
| James RodbergCFO | — | $203K | Oct 5, 2026 | — |
| Brenton TaylorEvp, Operations & R&D | — | $161K | Oct 5, 2026 | — |
SGHT stock: common questions
Are Sight Sciences, Inc. insiders buying SGHT stock?
In the past 12 months, 1 insiders reported open-market purchases of SGHT worth $185K. The latest was Director Staffan Encrantz bought $69K of SGHT at $4.88.
Are Sight Sciences, Inc. insiders selling SGHT stock?
6 insiders reported sales worth $2.9M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is SGHT's 52-week range?
Over the past year SGHT has traded between $3.20 and $9.36. It last closed at $8.89 on Oct 9, 2026.